Recently, the Anhui Provincial Veterinary Drug and Feed Supervision Institute, together with the Department of Animal Husbandry and Veterinary Medicine and the Wuhu Veterinary Management Service Center, conducted an on-site Good Manufacturing Practice (GMP) inspection of Leadsynbio’s wholly owned subsidiary—Anhui Liberty Pharmaceutical.

Following a comprehensive review, the company’s non-sterile Active Pharmaceutical Ingredient (API) production line (Grade D), covering Florfenicol and Thiamphenicol, was officially recognized as compliant with Veterinary GMP standards. The successful certification confirms the robustness of the company’s quality management system and marks another milestone in its commitment to excellence.

In 2024, Liberty Pharmaceutical completed a strategic expansion of its Florfenicol API production line, achieving an annual capacity of 3,200 tons of Florfenicol and 300 tons of Thiamphenicol. The new production lines are powered by a fully automated control system, enabling a standardized closed-loop process from raw material input to final product packaging. This upgrade significantly enhances production efficiency, product consistency, safety, and precision in process management.

Looking ahead, Liberty Pharmaceutical will continue to uphold the principle of “quality first.” By integrating intelligent manufacturing technologies into veterinary drug production, the company aims to provide highly reliable API products that meet the evolving needs of the global animal health industry.